Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15352040 | 0.85 | CYP2A6 (0.43) | CYP2A6MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL23088344 | 0.82 | CYP2A6 (0.45) | CYP2A6MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL15413750 | 0.82 | CYP2A6 (0.45) | CYP2A6MEN1KMT2AHTR6SIRT2 | |
| SCHEMBL29792679 | 0.82 | CYP2A6 (0.45) | CYP2A6MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL28605320 | 0.81 | CYP2A6 (0.43) | CYP2A6MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL12256751 | 0.81 | CYP2A6 (0.43) | CYP2A6MEN1KMT2ACYP1A2CYP2D6 | |
| SCHEMBL23088226 | 0.81 | CYP2A6 (0.47) | CYP2A6MEN1KMT2ADAOCYP1A2 | |
| SCHEMBL29792748 | 0.81 | CYP2A6 (0.47) | CYP2A6MEN1KMT2ADAOCYP1A2 | |
| SCHEMBL11166601 | 0.80 | CYP2A6 (0.39) | CYP2A6MEN1KMT2AMTNR1AMTNR1B | |
| SCHEMBL3587711 | 0.79 | TDP1 (0.64) | MEN1KMT2AMTNR1AMTNR1BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | GABRA1 1147/4885GABRB2 1148/4885CYP2A6 332/4885 |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | GABRA1 1101/4885GABRB2 1300/4885CYP2A6 363/4885 |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | GABRA1 1147/4885GABRB2 1148/4885CYP2A6 332/4885 |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | GABRA1 1101/4885GABRB2 1300/4885CYP2A6 363/4885 |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | GABRA1 1172/4885GABRB2 1229/4885CYP2A6 338/4885 |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | GABRA1 1172/4885GABRB2 1229/4885CYP2A6 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.